Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 18.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To earn an additional 4.0 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 18.0 Contact Hours.
Nurse Practitioner Session (Educational Session and Networking for Advanced Practitioners: Clinical Pearls for Practice)
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
This program is accredited for 2.0 contact hours which includes 2.0 hours of pharmacology in partnership with Partners in Healthcare Education, LLC. Partners in Healthcare Education, LLC is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education; Provider Number: 031206.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AbbVie; Agios Pharmaceuticals, Inc.; Astellas; AstraZeneca; BeiGene, Ltd.; Celgene Corporation; Daiichi Sankyo, Inc.; Dova Pharmaceuticals, Inc.; GlaxoSmithKline; Karyopharm; Kite Pharma, Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides, Inc.; Pfizer; Sanofi Genzyme; Seattle Genetics, Inc.; Servier Pharmaceuticals, LLC.; Takeda Oncology; and Verastem, Inc.
24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
CAR T Preconference Workshop at the PER® Winter Hematology® Meeting
Thursday, February 27, 2020
12:30 PM – 5:00 PM
Eden Roc Miami Beach
4525 Collins Avenue
Miami Beach, FL 33140
Click to view agenda
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Celgene Corporation; Kite Pharma, Inc.; and Legend Biotech USA Inc.
For patients with relapsed hematologic malignancies, the development of chimeric antigen receptor (CAR) T-cell therapy has provided new treatment options, with durable complete responses observed even in heavily pretreated patients. Multiple CAR T-cell approaches are being investigated in patients with leukemia, lymphoma, or myeloma. This workshop on CAR T-cell therapies will help you develop familiarity with applications of CAR T cells in patients with hematologic malignancies, including a discussion of real-world data and important aspects of managing treatment-related adverse events. You will also learn about future developments in cellular therapy, including overcoming resistance to CAR T-cell therapy, harnessing other immune cells for antitumor activity, and applying cellular therapy in solid tumors.
Benefits of attending the CAR T Preconference Workshop:
- Learn about the unique properties of CAR T-cell therapy and implications for patient management
- Increase your knowledge of clinical data on CAR T cells in patients with hematologic and other malignancies
- Develop strategies for the application of CAR T cells in your patients with hematologic malignancies
- Gain knowledge of managing treatment-related adverse events with CAR T cells
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
|Thursday, February 27, 2020||Moderator: Andre Goy, MD|
|12:30 PM||Welcome and Introductions||Andre Goy, MD|
|12:40 PM||Case/Audience Response System (ARS)|
|12:45 PM||Update in CAR T Cells in Lymphomas||Frederick L. Locke, MD|
|01:00 PM||Question-and-Answer Session|
|01:10 PM||What's New With CAR T Cells in Leukemia||Jae H. Park, MD|
|01:25 PM||Question-and-Answer Session|
|01:35 PM||Emerging CAR T-Cell Therapies in Myeloma||Noopur Raje, MD|
|01:50 PM||Question-and-Answer Session|
|02:00 PM||Overcoming Resistance to CAR T Cells||Yi Lin, MD, PhD|
|02:15 PM||Question-and-Answer Session|
|02:20 PM||Panel Discussion and Medical Crossfire®||
Moderator: Andre Goy, MD
Panelists: Yi Lin, MD, PhD
Frederick L. Locke, MD
Jae H. Park, MD
Noopur Raje, MD
|03:10 PM||The Potential of CAR NK Cells in Oncology||May Daher, MD|
|03:25 PM||Question-and-Answer Session|
|03:35 PM||Other Forms of Immunotherapy||Joshua Brody, MD|
|03:50 PM||Question-and-Answer Session|
|04:00 PM||CAR T Cells in Solid Tumors: Progress at Last?||Prasad S. Adusumilli, MD, FACS, FCCP|
|04:15 PM||Question-and-Answer Session|
|04:25 PM||Improving Cellular Therapy, Revisiting Stem Cell Transplantation||Alan Skarbnik, MD|
|04:40 PM||Question-and-Answer Session|
|04:45 PM||Panel Discussion and Medical Crossfire®||
Moderator: Andre Goy, MD
Panelists: Prasad S. Adusumilli, MD, FACS, FCCP
Joshua Brody, MD
May Daher, MD
|05:00 PM – 06:00 PM||Networking Reception|
Chairman and Executive Director
Lymphoma Division Chief, John Theurer Cancer Center
Chief Science Officer, RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University